Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roger Bedimo

Infectious Disease Dallas, TX Medical Doctor

NPI 1508879859 CMS profile 249538

4500 S Lancaster Rd, Suite 111-D, Dallas, TX 75216

Open in the dashboard

General payments

$269,277

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$706,638 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Roger Bedimo of Dallas, TX is reported in the CMS Open Payments database as having received $269,277 across 204 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $706,638 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,887 26
2024 General $64,602 44
2023 General $64,271 52
2022 General $23,611 23
2021 General $13,927 9
2020 General $20,292 9
2019 General $48,688 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Bedimo
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Roger Bedimo were reported at $33,887. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Roger Bedimo Infectious Disease median Middle half National median
2019 $48,688 $190 $60–$862 $163
2020 $20,292 $124 $32–$606 $114
2021 $13,927 $148 $38–$905 $132
2022 $23,611 $166 $50–$834 $149
2023 $64,271 $171 $57–$787 $160
2024 $64,602 $176 $52–$752 $164
2025 $33,887 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ViiV Healthcare Company $88,617 53 payments
  2. Merck Sharp & Dohme Corporation $68,779 57 payments
  3. Gilead Sciences, Inc. $36,044 34 payments
  4. Shionogi Inc $26,183 29 payments
  5. Theratechnologies Inc. $19,936 16 payments
  6. EMD Serono, Inc. $19,515 8 payments
  7. GlaxoSmithKline, LLC. $5,808 1 payment
  8. Janssen Products, LP $4,300 5 payments
  9. Janssen Scientific Affairs, LLC $94 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $190,942 64 payments
  2. Travel and Lodging $48,967 61 payments
  3. Honoraria $15,500 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,960 1 payment
  5. Food and Beverage $4,927 69 payments
  6. Education $1,886 3 payments
  7. Grant $94 1 payment
Products named General payments · program years 2019–2025
  1. ISENTRESS $8,964 7 payments
  2. PIFELTRO $8,948 6 payments
  3. STEGLATRO $8,934 5 payments
  4. DELSTRIGO $8,924 13 payments
  5. CABENUVA $7,822 3 payments
  6. DOVATO $7,120 5 payments
  7. Veklury $6,293 11 payments
  8. EGRIFTA SV $5,246 4 payments
  9. SYMTUZA $4,300 5 payments
  10. Fetroja $4,018 6 payments
  11. Other $8,431 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record